View All HCPCS Sections

• M1400

  Patients who died during the follow-up period

• M1401

  Stages i-iii breast cancer

• M1402

  Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group

• M1403

  Patients with baseline and follow-up promis surveys documented in the medical record

• M1404

  Patients on a therapeutic clinical trial

• M1405

  Patients with recurrence/disease progression

• M1406

  Patients who leave the practice during the follow-up period

• M1407

  Patients who died during the follow-up period

• M1408

  Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer

• M1409

  Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis

• M1410

  Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis

• M1411

  Currently on first-line immune checkpoint inhibitors without chemotherapy

• M1412

  Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement

• M1413

  Patients who had a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy

• M1414

  Documentation of medical reason(s) for not performing the pd-l1 biomarker expression test prior to initiation of first-line immune checkpoint inhibitor therapy (e.g., patient is in an urgent or emergent situation where delay of treatment would jeopardize the patient's health status; other medical reasons/contraindication)

• M1415

  Patients who did not have a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy

• M1416

  Patient received hospice services any time during the performance period

• M1417

  Patients who are up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination

• M1418

  Patients who are not up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination because of a medical contraindication documented by clinician

• M1419

  Patients who are not up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination

• M1420

  Complete ophthalmologic care mips value pathway

• M1421

  Dermatological care mips value pathway

• M1422

  Gastroenterology care mips value pathway

• M1423

  Optimal care for patients with urologic conditions mips value pathway

• M1424

  Pulmonology care mips value pathway

• M1425

  Surgical care mips value pathway

• M1426

  Encounters conducted via telehealth

• M1427

  Documentation of medical reason(s) for performing a bone scan (including documented pain related to prostate cancer, salvage therapy, other medical reasons)

• M1428

  Patients who have bilateral absence of eyes any time during the patient's history through the end of the measurement period

• M1429

  Retinal exam finding with evidence of retinopathy in left, right or both eyes with severity level documented

• M1430

  Retinal exam finding without evidence of retinopathy in both eyes with severity level documented (in measurement year or in the prior year)

• M1431

  Encounters conducted via telehealth

• M1432

  Encounters conducted via telehealth

• M1433

  Patient on oral chemotherapy on or within 30 days before denominator eligible encounter

• M1434

  Patient on oral chemotherapy on or within 30 days after denominator eligible encounter

• M1435

  Patient on oral chemotherapy during the performance period

• M1436

  Encounters conducted via telehealth

• M1437

  Encounters conducted via telehealth

• M1438

  Time last known well to hospital arrival less than or equal to 3.5 hours (<= 210 minutes)

• M1439

  Significant ocular conditions that impact the visual outcome of surgery

• M1440

  Encounters conducted via telehealth

• M1441

  Encounter corresponds to initial diagnosis of sleep apnea or first contact with sleep apnea diagnosed patient

• M1442

  Encounters conducted via telehealth

• M1443

  Encounters conducted via telehealth

• M1444

  Delivery at < 39 weeks of gestation

• M1445

  Postpartum care visit before or at 12 weeks of giving birth

• M1446

  Patients who died any time prior to the end of the measure assessment period

• M1447

  Patients with an active diagnosis of bipolar disorder any time prior to the end of the measure assessment period

• M1448

  Patients with an active diagnosis of personality disorder any time prior to the end of the measure assessment period

• M1449

  Patients with an active diagnosis of schizophrenia or psychotic disorder any time prior to the end of the measure assessment period

---

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/3/2026

CPT^® is a registered trademark of the American Medical Association (AMA). All rights reserved.